Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.
First CPT Code for AI Prostate Cancer Imaging Issued for Avenda Health
What You Should Know: – Avenda Health’s AI mapping tool for prostate cancer, Unfold AI™, has received significant recognition by obtaining a new Category III
November 2, 2023